Best of IBD Summit: Navigating Loss of Response, Maintenance Therapy, and Fistulizing CD

Overview

Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by educational grants from Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.

Activity Description

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the main subtypes, is a chronic relapsing condition characterized by an overly active immune response in the gut, resulting in bowel inflammation and ulceration. Given the increasing prevalence of disease and influx of available biologics and small molecule therapies, gastroenterologists can benefit from ongoing education regarding the diagnosis, classification, and evidence-based management of patients with IBD. In the Best of IBD Summit, available in 2 parts, expert clinicians discuss the latest updates in diagnosing and managing IBD. Faculty evaluate the safety and efficacy of current and emerging therapies and discuss optimal positioning of available agents.

Target Audience

The intended audience for this activity is gastroenterologists, internists, nurse practitioners, physician associates, and other health care professionals involved in the management of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize the severity of inflammatory bowel disease (IBD) and use of therapeutic drug monitoring to inform treatment decisions.
• Evaluate pharmacological therapies for IBD based on optimal positioning of available agents.
• Review the safety and efficacy of current and emerging treatment options for IBD.
• Examine the use of biologics and small molecules for the treatment of patients with IBD, including their clinical implications.
• Describe the components of the treat-to-target approach for patients with IBD.

Activity Co-Chairs

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL

Corey A. Siegel, MD, MS
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, Inflammatory Bowel Disease Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Faculty

Maria T. Abreu, MD
Director, Crohn's and Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Miami, FL

Marla C. Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology
Mount Sinai Kravis Children’s Hospital
Icahn School of Medicine at Mount Sinai
New York, NY

Planning Committee

Jessica Caron, MS
Patient Advocate
Founder, www.Chronically-Jess.com
Goffstown, NH

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL

Edward V. Loftus, Jr., MD
Professor of Medicine
Co-Director of Advanced IBD Fellowship
Consultant, Division of Gastroenterology
Mayo Clinic
Rochester, MN

Millie D. Long, MD, MPH
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Associates (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME. PAs may receive a maximum of 1.5 credit hours for completing this program.

This enduring material is approved for 1 year from the date of original release, February 28, 2023, to February 27, 2024.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Co-Chairs, Faculty, and Planning Committee report the following relevant financial relationship(s)

Maria T. Abreu, MD
Consultant: AbbVie, Arena, Bristol Myers Squibb, Celsius, Gilead, Helmsley Charitable Trust, Janssen, Lilly, Microba, Pfizer, Prometheus, UCB, WebMD
Speaker Contracted by Ineligible Company: Alimentiv, Janssen, Takeda

Jessica Caron, MS
No relevant financial relationships to disclose.

Marla C. Dubinsky, MD
Consultant: AbbVie, Arena, Celgene, Gilead, Janssen, Lilly, Pfizer, Prometheus Labs, Prometheus Biosciences, Takeda
Individual Stocks and Stock Options: Trellus Health

Stephen B. Hanauer, MD
Consultant: AbbVie, Allergan, Amgen, Arena, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalys Pacific, Celgene, Cosmos, Covance, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung, Bioepis, Seres, Sorriso, TLL Pharma, Takeda, UCB, VHsquared
Speaker Contracted by Ineligible Company: AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda
Independent Research Contractor (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB
Data Safety Monitoring Board: Arena, Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Prometheus, Protagonist

Edward V. Loftus, Jr., MD
Consultant: AbbVie, Alvotech, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, CALIBR, Celgene, Celltrion Healthcare, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Lilly, Morphic, Ono, Pfizer, Protagonist, Scipher Medicine, Sun, Surrozen, Takeda, UCB
Independent Research Contractor: AbbVie, Bristol Myers Squibb, Celgene/Receptos, Genentech, Gilead, Janssen, Pfizer, Takeda, Theravance, UCB
Individual Stocks and Stock Options: Exact Sciences

Millie D. Long, MD, MPH
Consultant: AbbVie, Bristol Myers Squibb, Genentech, Janssen, Lilly, Pfizer, Prometheus, Roche, Takeda, Target PharmaSolutions
Independent Research Contractor: Pfizer, Takeda

Miguel Regueiro, MD, AGAF, FACG, FACP
Consultant: AbbVie, Alfasigma S.p.A., Allergan, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca, Pfizer, Prometheus, Salix, Seres, Takeda, TARGET ParmaSolutions, UCB
Unrestricted Educational Grants: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Gilead, Janssen, Lilly, Pfizer, Takeda, UCB

David T. Rubin, MD
Consultant: AbbVie, Alimentiv, AltruBio, Arena, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix, Boehringer Ingelheim, Bristol Myers Squibb, Celgene/Syneos, Connect Biopharma, Datos Health, EcoR1, Evinature, Genentech/Roche, Gilead, Ironwood Pharmaceuticals, Iterative Scopes, Janssen, Kaleido Biosciences, Lilly, Pfizer, Prometheus, Reistone, Seres, Takeda, Target RWE, Techlab, Trellus Health
Independent Research Contractor: Takeda
Individual Stocks and Stock Options: Altrubio, Datos Health

Corey A. Siegel, MD, MS
Consultant: AbbVie, Bristol Myers Squibb, Fresenius, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus, Takeda, Trellus Health
Independent Research Contractor: AbbVie, Janssen, Pfizer, Takeda
Equity Interest: MiTest Health

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. ©2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com